Diffuse Intrinsic Pontine Gliomas (DIPG) Market Research Report 2030 | DelveInsight

Diffuse Intrinsic Pontine Gliomas (DIPG) (also known as Pontine Glioma or Brainstem Glioma) are highly aggressive and difficult to treat brain tumors found at the base of the brain. They are glial tumors that arise from the brain's glial tissue (tissue made up of cells that help support and protect the brain's neurons). These tumors are found in an area of the brainstem (the lowest, stem-like part of the brain) called the pons, which controls many of the body’s most vital functions, such as breathing, blood pressure, and heart rate.

DelveInsight's "Diffuse Intrinsic Pontine Glioma (DIPG) Market Report 2030"delivers an in-depth understanding of the Diffuse Intrinsic Pontine Glioma (DIPG) , historical and forecasted epidemiology as well as the Diffuse Intrinsic Pontine Glioma (DIPG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Diffuse Intrinsic Pontine Glioma (DIPG) Disease Understanding and Treatment Algorithm

The DelveInsight Diffuse Intrinsic Pontine Glioma (DIPG) market report gives a thorough understanding of the Diffuse Intrinsic Pontine Glioma (DIPG) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Symptoms:

The symptoms of DIPG usually develop very rapidly before diagnosis, reflecting the fast growth of the tumors. The most common symptoms include rapidly developing problems controlling eye movements, facial expressions, speech, chewing, and swallowing (due to problems in the cranial nerves), weakness in the arms and legs, problems with walking and coordination.

Click here and get access to free report.

Diffuse Intrinsic Pontine Glioma (DIPG) Epidemiology  

The Diffuse Intrinsic Pontine Glioma (DIPG) epidemiology division provide insights about historical and current Diffuse Intrinsic Pontine Glioma (DIPG) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key findings:

· Diffuse intrinsic pontine gliomas account for 10% of all childhood central nervous system tumors.

· Approximately 300 children in the US are diagnosed with DIPG each year. While DIPGs are usually diagnosed when children are between the ages of 5 and 9, they can occur at any age in childhood. These tumors occur in boys and girls equally and do not generally appear in adults.

· About 10–20% of all childhood brain tumors are DIPG or brainstem gliomas. They are more common in children between the ages of 5 and 10 years but can occur at any age in childhood. Though rarer, they can also occur in adults.

View epidemiology insights of the report: https://www.delveinsight.com/report-store/diffuse-intrinsic-pontine-glioma-dipg-epidemiology-forecast

Diffuse Intrinsic Pontine Glioma (DIPG) Drug Chapters

The dynamics of Diffuse Intrinsic Pontine Glioma (DIPG) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies and incremental healthcare spending across the world. The launch of emerging therapies is expected during the forecast period of 2019–2028.

Key players, such as Sumitomo Dainippon Pharma, Regeneron Pharmaceuticals, Novartis, and many others are developing therapies for the treatment of patients with Diffuse Intrinsic Pontine Glioma (DIPG). Sumitomo Dainippon Pharma (DSP-7888), Regeneron Pharmaceuticals (Cemiplimab), Novartis (Ribociclib), and others along with other compelling treatment options in the clinical trials are expected to increase the overall market size of Diffuse Intrinsic Pontine Glioma (DIPG) in the upcoming years.

Drug chapter segment of the Diffuse Intrinsic Pontine Glioma (DIPG) report encloses the detailed analysis of Diffuse Intrinsic Pontine Glioma (DIPG) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

View pipeline insights of the report: https://www.delveinsight.com/report-store/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight

Diffuse Intrinsic Pontine Glioma (DIPG) Market Outlook

The market for Diffuse Intrinsic Pontine Glioma (DIPG) does not hold any approved therapy. There are a number of treatments recommended by medical professionals. Some of them help to treat the tumor while others are intended to address complications of the disease or side effects of the treatment.

The Diffuse Intrinsic Pontine Glioma (DIPG) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Diffuse Intrinsic Pontine Glioma (DIPG) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Diffuse Intrinsic Pontine Glioma (DIPG) market in 7MM is expected to change in the study period 2017-2030.

Request for sample pages of the report: https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-market

 

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more